|
1
|
Rawla P: Epidemiology of prostate cancer.
World J Oncol. 10:63–89. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pernar CH, Ebot EM, Wilson KM and Mucci
LA: The epidemiology of prostate cancer. Cold Spring Harb Perspect
Med. 8:a0303612018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vietri MT, D'Elia G, Caliendo G, Resse M,
Casamassimi A, Passariello L, Albanese L, Cioffi M and Molinari AM:
Hereditary prostate cancer: Genes related, target therapy and
prevention. Int J Mol Sci. 22:37532021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ahmed HU, El-Shater Bosaily A, Brown LC,
Gabe R, Kaplan R, Parmar MK, Collaco-Moraes Y, Ward K, Hindley RG,
Freeman A, et al: Diagnostic accuracy of multi-parametric MRI and
TRUS biopsy in prostate cancer (PROMIS): A paired validating
confirmatory study. Lancet. 389:815–822. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Descotes JL: Diagnosis of prostate cancer.
Asian J Urol. 6:129–136. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wadosky KM and Koochekpour S: Molecular
mechanisms underlying resistance to androgen deprivation therapy in
prostate cancer. Oncotarget. 7:64447–64470. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chi K, Hotte SJ, Joshua AM, North S, Wyatt
AW, Collins LL and Saad F: Treatment of mCRPC in the
AR-axis-targeted therapy-resistant state. Ann Oncol. 26:2044–2056.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shah H and Vaishampayan U: Therapy of
advanced prostate cancer: Targeting the androgen receptor axis in
earlier lines of treatment. Target Oncol. 13:679–689. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Heidenreich A, Bastian PJ, Bellmunt J,
Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T,
Zattoni F, et al: EAU guidelines on prostate cancer. Part II:
Treatment of advanced, relapsing, and castration-resistant prostate
cancer. Eur Urol. 65:467–479. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Antonov P, Raycheva G and Popov V:
Unexpected long-term survival in an adult patient with metastatic
prostate cancer. Urol Case Rep. 37:1016342021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bubendorf L, Schöpfer A, Wagner U, Sauter
G, Moch H, Willi N, Gasser TC and Mihatsch MJ: Metastatic patterns
of prostate cancer: An autopsy study of 1,589 patients. Hum Pathol.
31:578–583. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu D, Kuai Y, Zhu R, Zhou C, Tao Y, Han W
and Chen Q: Prognosis of prostate cancer and bone metastasis
pattern of patients: A SEER-based study and a local hospital based
study from China. Sci Rep. 10:91042020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nieder C, Haukland E, Pawinski A and
Dalhaug A: Pathologic fracture and metastatic spinal cord
compression in patients with prostate cancer and bone metastases.
BMC Urol. 10:232010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Veldurthy V, Wei R, Oz L, Dhawan P, Jeon
YH and Christakos S: Vitamin D, calcium homeostasis and aging. Bone
Res. 4:160412016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen X, Wang Z, Duan N, Zhu G, Schwarz EM
and Xie C: Osteoblast-osteoclast interactions. Connect Tissue Res.
59:99–107. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Suva LJ, Washam C, Nicholas RW and Griffin
RJ: Bone metastasis: Mechanisms and therapeutic opportunities. Nat
Rev Endocrinol. 7:208–218. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nordstrand A, Bovinder Ylitalo E, Thysell
E, Jernberg E, Crnalic S, Widmark A, Bergh A, Lerner UH and
Wikström P: Bone cell activity in clinical prostate cancer bone
metastasis and its inverse relation to tumor cell androgen receptor
activity. Int J Mol Sci. 19:12232018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wong SK, Mohamad NV, Giaze TR, Chin KY,
Mohamed N and Ima-Nirwana S: Prostate cancer and bone metastases:
The underlying mechanisms. Int J Mol Sci. 20:25872019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fares J, Fares MY, Khachfe HH, Salhab HA
and Fares Y: Molecular principles of metastasis: A hallmark of
cancer revisited. Signal Transduct Target Ther. 5:282020.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Paget S: The distribution of secondary
growths in cancer of the breast. Lancet. 133:571–573. 1889.
View Article : Google Scholar
|
|
21
|
Macedo F, Ladeira K, Pinho F, Saraiva N,
Bonito N, Pinto L and Goncalves F: Bone metastases: An overview.
Oncol Rev. 11:3212017.PubMed/NCBI
|
|
22
|
Mundy GR: Metastasis to bone: Causes,
consequences and therapeutic opportunities. Nat Rev Cancer.
2:584–593. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Conti G, La Torre G, Cicalese V,
Micheletti G, Ludovico MG, Vestita GD, Cottonaro G, Introini C and
Cecchi M: Prostate cancer metastases to bone: Observational study
for the evaluation of clinical presentation, course and treatment
patterns. Presentation of the METAURO protocol and of patient
baseline features. Arch Ital Urol Androl. 80:59–64. 2008.PubMed/NCBI
|
|
24
|
Kitajima K, Yamamoto S, Kawanaka Y, Komoto
H, Shimatani K, Hanasaki T, Taguchi M, Nagasawa S, Yamada Y,
Kanematsu A and Yamakado K: Assessment of the viability and
treatment response of bone metastases in patients with metastatic
castration-resistant prostate cancer using choline PET/CT. Medicine
(Baltimore). 100:e262062021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lin SC, Yu-Lee LY and Lin SH: Osteoblastic
factors in prostate cancer bone metastasis. Curr Osteoporos Rep.
16:642–647. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Roudier MP, Morrissey C, True LD, Higano
CS, Vessella RL and Ott SM: Histopathological assessment of
prostate cancer bone osteoblastic metastases. J Urol.
180:1154–1160. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Garnero P, Buchs N, Zekri J, Rizzoli R,
Coleman RE and Delmas PD: Markers of bone turnover for the
management of patients with bone metastases from prostate cancer.
Br J Cancer. 82:858–864. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Khan MA and Partin AW: Bisphosphonates in
metastatic prostate cancer. Rev Urol. 5:204–206. 2003.PubMed/NCBI
|
|
29
|
Kim JM, Lin C, Stavre Z, Greenblatt MB and
Shim JH: Osteoblast-osteoclast communication and bone homeostasis.
Cells. 9:20732020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cheville JC, Tindall D, Boelter C, Jenkins
R, Lohse CM, Pankratz VS, Sebo TJ, Davis B and Blute ML: Metastatic
prostate carcinoma to bone: Clinical and pathologic features
associated with cancer-specific survival. Cancer. 95:1028–1036.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ribelli G, Simonetti S, Iuliani M, Rossi
E, Vincenzi B, Tonini G, Pantano F and Santini D: Osteoblasts
promote prostate cancer cell proliferation through androgen
receptor independent mechanisms. Front Oncol. 11:7898852021.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kirschenbaum A, Liu XH, Yao S, Leiter A
and Levine AC: Prostatic acid phosphatase is expressed in human
prostate cancer bone metastases and promotes osteoblast
differentiation. Ann N Y Acad Sci. 1237:64–70. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kirschenbaum A, Izadmehr S, Yao S,
O'Connor-Chapman KL, Huang A, Gregoriades EM, Yakar S and Levine
AC: Prostatic acid phosphatase alters the RANKL/OPG system and
induces osteoblastic prostate cancer bone metastases.
Endocrinology. 157:4526–4533. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen G, Sircar K, Aprikian A, Potti A,
Goltzman D and Rabbani SA: Expression of RANKL/RANK/OPG in primary
and metastatic human prostate cancer as markers of disease stage
and functional regulation. Cancer. 107:289–298. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Udagawa N, Takahashi N, Yasuda H, Mizuno
A, Itoh K, Ueno Y, Shinki T, Gillespie MT, Martin TJ, Higashio K
and Suda T: Osteoprotegerin produced by osteoblasts is an important
regulator in osteoclast development and function. Endocrinology.
141:3478–3484. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Corey E, Brown LG, Kiefer JA, Quinn JE,
Pitts TE, Blair JM and Vessella RL: Osteoprotegerin in prostate
cancer bone metastasis. Cancer Res. 65:1710–1718. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Brown JM, Corey E, Lee ZD, True LD, Yun
TJ, Tondravi M and Vessella RL: Osteoprotegerin and rank ligand
expression in prostate cancer. Urology. 57:611–616. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Holen I, Croucher PI, Hamdy FC and Eaton
CL: Osteoprotegerin (OPG) is a survival factor for human prostate
cancer cells. Cancer Res. 62:1619–1623. 2002.PubMed/NCBI
|
|
39
|
Chiao JW, Moonga BS, Yang YM, Kancherla R,
Mittelman A, Wu-Wong JR and Ahmed T: Endothelin-1 from prostate
cancer cells is enhanced by bone contact which blocks osteoclastic
bone resorption. Br J Cancer. 83:360–365. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Fizazi K, Yang J, Peleg S, Sikes CR,
Kreimann EL, Daliani D, Olive M, Raymond KA, Janus TJ, Logothetis
CJ, et al: Prostate cancer cells-osteoblast interaction shifts
expression of growth/survival-related genes in prostate cancer and
reduces expression of osteoprotegerin in osteoblasts. Clin Cancer
Res. 9:2587–2597. 2003.PubMed/NCBI
|
|
41
|
Yin JJ, Mohammad KS, Käkönen SM, Harris S,
Wu-Wong JR, Wessale JL, Padley RJ, Garrett IR, Chirgwin JM and
Guise TA: A causal role for endothelin-1 in the pathogenesis of
osteoblastic bone metastases. Proc Natl Acad Sci USA.
100:10954–10959. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Valta MP, Tuomela J, Bjartell A, Valve E,
Väänänen HK and Härkönen P: FGF-8 is involved in bone metastasis of
prostate cancer. Int J Cancer. 123:22–31. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Quiroz-Munoz M, Izadmehr S, Arumugam D,
Wong B, Kirschenbaum A and Levine AC: Mechanisms of osteoblastic
bone metastasis in prostate cancer: Role of prostatic acid
phosphatase. J Endocr Soc. 3:655–664. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ikuerowo SO, Omisanjo OA, Bioku MJ, Ajala
MO, Mordi VP and Esho JO: Prevalence and characteristics of
prostate cancer among participants of a community-based screening
in Nigeria using serum prostate specific antigen and digital rectal
examination. Pan Afr Med J. 15:1292013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Idowu BM: Prostate carcinoma presenting
with diffuse osteolytic metastases and supraclavicular
lymphadenopathy mimicking multiple myeloma. Clin Case Rep.
6:253–257. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Maharaj B, Kalideen JM, Leary WP and
Pudifin DJ: Carcinoma of the prostate with multiple osteolytic
metastases simulating multiple myeloma. A case report. S Afr Med J.
70:227–228. 1986.PubMed/NCBI
|
|
47
|
Fukuoka H, Ishibashi Y, Masuda M, Gotoh A,
Murai T and Kitamura H: A case of prostatic carcinoma with
osteolytic bone metastases. Hinyokika Kiyo. 34:1805–1809. 1988.(In
Japanese). PubMed/NCBI
|
|
48
|
Migita T, Maeda K and Ogata N: A case of
prostate cancer associated with osteolytic bone metastases.
Hinyokika Kiyo. 45:371–374. 1999.(In Japanese). PubMed/NCBI
|
|
49
|
Rajendiran G, Green L and Chhabra G: A
rare presentation of prostate cancer with diffuse osteolytic
metastases and PSA of 7242 ng/ml. Int J Case Rep Image. 2:16–20.
2011. View Article : Google Scholar
|
|
50
|
Segamwenge IL, Mgori NK, Abdallahyussuf S,
Mukulu CN, Nakangombe P, Ngalyuka PK and Kidaaga F: Cancer of the
prostate presenting with diffuse osteolytic metastatic bone
lesions: A case report. J Med Case Rep. 6:4252012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Sharma P, Karunanithi S, Singh Dhull V,
Jain S, Bal C and Kumar R: Prostate cancer with lytic bone
metastases: 18F-fluorodeoxyglucose positron emission
tomography-computed tomography for diagnosis and monitoring
response to medical castration therapy. Indian J Nucl Med.
28:178–179. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Bird VY, Domino PM, Sutkowski R, Stillings
SA and Trejo-Lopez JA: Prostate cancer with metastatic lytic bone
lesions: Positive bone scan post docetaxel chemotherapy in the
setting of clinically successful treatment. Urol Case Rep. 6:12–14.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Rummel K, Benson J and Roller L: Prostate
adenocarcinoma with osteolytic metastases: Case report and review
of the literature. Radiol Case Rep. 16:3565–3568. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Bryden AAG, Hoyland JA, Freemont AJ,
Clarke NW and George NJR: Parathyroid hormone related peptide and
receptor expression in paired primary prostate cancer and bone
metastases. Br J Cancer. 86:322–325. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Huang JC, Sakata T, Pfleger LL, Bencsik M,
Halloran BP, Bikle DD and Nissenson RA: PTH differentially
regulates expression of RANKL and OPG. J Bone Miner Res.
19:235–244. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Ongkeko WM, Burton D, Kiang A, Abhold E,
Kuo SZ, Rahimy E, Yang M, Hoffman RM, Wang-Rodriguez J and Deftos
LJ: Parathyroid hormone related-protein promotes
epithelial-to-mesenchymal transition in prostate cancer. PLoS One.
9:e858032014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Chen X, Zhi X, Wang J and Su J: RANKL
signaling in bone marrow mesenchymal stem cells negatively
regulates osteoblastic bone formation. Bone Res. 6:342018.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Ikebuchi Y, Aoki S, Honma M, Hayashi M,
Sugamori Y, Khan M, Kariya Y, Kato G, Tabata Y, Penninger JM, et
al: Coupling of bone resorption and formation by RANKL reverse
signalling. Nature. 561:195–200. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Wang M, Xia F, Wei Y and Wei X: Molecular
mechanisms and clinical management of cancer bone metastasis. Bone
Res. 8:302020. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Feng J, Xu X, Li B, Brown E, Farris AB,
Sun SY and Yang JJ: Prostate cancer metastatic to bone has higher
expression of the calcium-sensing receptor (CaSR) than primary
prostate cancer. Receptors Clin Investig. 1:e2702014.PubMed/NCBI
|
|
61
|
Kuchimaru T, Hoshino T, Aikawa T, Yasuda
H, Kobayashi T, Kadonosono T and Kizaka-Kondoh S: Bone resorption
facilitates osteoblastic bone metastatic colonization by
cooperation of insulin-like growth factor and hypoxia. Cancer Sci.
105:553–559. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Russo S, Scotto di Carlo F and
Gianfrancesco F: The osteoclast traces the route to bone tumors and
metastases. Front Cell Dev Biol. 10:8863052022. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Hadjidakis DJ and Androulakis II: Bone
remodeling. Ann N Y Acad Sci. 1092:385–396. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Schwartz MA, Schaller MD and Ginsberg MH:
Integrins: Emerging paradigms of signal transduction. Annu Rev Cell
Dev Biol. 11:549–599. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Schneider JG, Amend SR and Weilbaecher KN:
Integrins and bone metastasis: Integrating tumor cell and stromal
cell interactions. Bone. 48:54–65. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Singh R, Kapur N, Mir H, Singh N, Lillard
JW Jr and Singh S: CXCR6-CXCL16 axis promotes prostate cancer by
mediating cytoskeleton rearrangement via Ezrin activation and αvβ3
integrin clustering. Oncotarget. 7:7343–7353. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Lu J, Doyle AD, Shinsato Y, Wang S,
Bodendorfer MA, Zheng M and Yamada KM: Basement membrane regulates
fibronectin organization using sliding focal adhesions driven by a
contractile winch. Dev Cell. 52:631–646.e4. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
He Y, Liu XD, Chen ZY, Zhu J, Xiong Y, Li
K, Dong JH and Li X: Interaction between cancer cells and stromal
fibroblasts is required for activation of the uPAR-uPA-MMP-2
cascade in pancreatic cancer metastasis. Clin Cancer Res.
13:3115–3124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Sun LC, Luo J, Mackey LV, Fuselier JA and
Coy DH: A conjugate of camptothecin and a somatostatin analog
against prostate cancer cell invasion via a possible signaling
pathway involving PI3K/Akt, alphaVbeta3/alphaVbeta5 and MMP-2/-9.
Cancer Lett. 246:157–166. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Somanath PR, Malinin NL and Byzova TV:
Cooperation between integrin alphavbeta3 and VEGFR2 in
angiogenesis. Angiogenesis. 12:177–185. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Dong Y, Xie X, Wang Z, Hu C, Zheng Q, Wang
Y, Chen R, Xue T, Chen J, Gao D, et al: Increasing matrix stiffness
upregulates vascular endothelial growth factor expression in
hepatocellular carcinoma cells mediated by integrin β1. Biochem
Biophys Res Commun. 444:427–432. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Tang L, Xu M, Zhang L, Qu L and Liu X:
Role of αVβ3 in prostate cancer: Metastasis initiator and important
therapeutic target. Onco Targets Ther. 13:7411–7422. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Brown NF and Marshall JF:
Integrin-mediated TGFβ activation modulates the tumour
microenvironment. Cancers (Basel). 11:12212019. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Wheelock MJ, Shintani Y, Maeda M, Fukumoto
Y and Johnson KR: Cadherin switching. J Cell Sci. 121:727–735.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Hussain M, Le Moulec S, Gimmi C, Bruns R,
Straub J and Miller K; PERSEUS Study Group, : Differential effect
on bone lesions of targeting integrins: Randomized phase II trial
of abituzumab in patients with metastatic castration-resistant
prostate cancer. Clin Cancer Res. 22:3192–3200. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Gheldof A and Berx G: Cadherins and
epithelial-to-mesenchymal transition. Prog Mol Biol Transl Sci.
116:317–336. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Bryden AAG, Hoyland JA, Freemont AJ,
Clarke NW, Schembri Wismayer D and George NJR: E-cadherin and
beta-catenin are down-regulated in prostatic bone metastases. BJU
Int. 89:400–403. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Jennbacken K, Tesan T, Wang W, Gustavsson
H, Damber JE and Welén K: N-cadherin increases after androgen
deprivation and is associated with metastasis in prostate cancer.
Endocr Relat Cancer. 17:469–479. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Cui Y and Yamada S: N-cadherin dependent
collective cell invasion of prostate cancer cells is regulated by
the N-terminus of α-catenin. PLoS One. 8:e550692013. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Sun Y, Jing J, Xu H, Xu L, Hu H, Tang C,
Liu S, Wei Q, Duan R, Guo J and Yang L: N-cadherin inhibitor
creates a microenvironment that protect TILs from immune
checkpoints and Treg cells. J Immunother Cancer. 9:e0021382021.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Tanaka H, Kono E, Tran CP, Miyazaki H,
Yamashiro J, Shimomura T, Fazli L, Wada R, Huang J, Vessella RL, et
al: Monoclonal antibody targeting of N-cadherin inhibits prostate
cancer growth, metastasis and castration resistance. Nat Med.
16:1414–1420. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Reily C, Stewart TJ, Renfrow MB and Novak
J: Glycosylation in health and disease. Nat Rev Nephrol.
15:346–366. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Garnham R, Scott E, Livermore KE and
Munkley J: ST6GAL1: A key player in cancer. Oncol Lett. 18:983–989.
2019.PubMed/NCBI
|
|
84
|
Bindeman WE and Fingleton B: Glycosylation
as a regulator of site-specific metastasis. Cancer Metastasis Rev.
41:107–129. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Sottnik JL, Daignault-Newton S, Zhang X,
Morrissey C, Hussain MH, Keller ET and Hall CL: Integrin alpha2beta
1 (α2β1) promotes prostate cancer skeletal metastasis. Clin Exp
Metastasis. 30:569–578. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Van Slambrouck S, Groux-Degroote S,
Krzewinski-Recchi MA, Cazet A, Delannoy P and Steelant WF:
Carbohydrate-to-carbohydrate interactions between α2,3-linked
sialic acids on α2 integrin subunits and asialo-GM1 underlie the
bone metastatic behaviour of LNCAP-derivative C4-2B prostate cancer
cells. Biosci Rep. 34:e001382014. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Julien S, Ivetic A, Grigoriadis A, QiZe D,
Burford B, Sproviero D, Picco G, Gillett C, Papp SL, Schaffer L, et
al: Selectin ligand sialyl-Lewis × antigen drives metastasis of
hormone-dependent breast cancers. Cancer Res. 71:7683–7693. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Barthel SR, Gavino JD, Wiese GK, Jaynes
JM, Siddiqui J and Dimitroff CJ: Analysis of glycosyltransferase
expression in metastatic prostate cancer cells capable of rolling
activity on microvascular endothelial (E)-selectin. Glycobiology.
18:806–817. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Gao J, Li T, Mo Z, Hu Y, Yi Q, He R, Zhu
X, Zhou X, She S and Chen Y: Overexpression of the galectin-3
during tumor progression in prostate cancer and its clinical
implications. Int J Clin Exp Pathol. 11:839–846. 2018.PubMed/NCBI
|
|
90
|
Nakajima K, Kho DH, Yanagawa T, Harazono
Y, Hogan V, Chen W, Ali-Fehmi R, Mehra R and Raz A: Galectin-3
cleavage alters bone remodeling: different outcomes in breast and
prostate cancer skeletal metastasis. Cancer Res. 76:1391–1402.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
van Zijl F, Krupitza G and Mikulits W:
Initial steps of metastasis: Cell invasion and endothelial
transmigration. Mutat Res. 728:23–34. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Pouliot N, Pearson HB and Burrows A:
Investigating metastasis using in vitro platforms. Madame Curie
Bioscience Database [Internet] Austin (TX): Landes Bioscience;
2013
|
|
93
|
Hao J, Madigan MC, Khatri A, Power CA,
Hung TT, Beretov J, Chang L, Xiao W, Cozzi PJ, Graham PH, et al: In
vitro and in vivo prostate cancer metastasis and chemoresistance
can be modulated by expression of either CD44 or CD147. PLoS One.
7:e407162012. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Li W, Qian L, Lin J, Huang G, Hao N, Wei
X, Wang W and Liang J: CD44 regulates prostate cancer
proliferation, invasion and migration via PDK1 and PFKFB4.
Oncotarget. 8:65143–65151. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Fang F, Li Q, Wu M, Nie C, Xu H and Wang
L: CD147 promotes epithelial-mesenchymal transition of prostate
cancer cells via the Wnt/β-catenin pathway. Exp Ther Med.
20:3154–3160. 2020.PubMed/NCBI
|
|
96
|
Joyce JA and Pollard JW:
Microenvironmental regulation of metastasis. Nat Rev Cancer.
9:239–252. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Guo S and Deng CX: Effect of stromal cells
in tumor microenvironment on metastasis initiation. Int J Biol Sci.
14:2083–2093. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Jasuja H, Kar S, Katti DR and Katti KS:
Perfusion bioreactor enabled fluid-derived shear stress conditions
for novel bone metastatic prostate cancer testbed. Biofabrication.
13:2021. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Fong ELS, Wan X, Yang J, Morgado M, Mikos
AG, Harrington DA, Navone NM and Farach-Carson MC: A 3D in vitro
model of patient-derived prostate cancer xenograft for controlled
interrogation of in vivo tumor-stromal interactions. Biomaterials.
77:164–172. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Hepburn AC, Curry EL, Moad M, Steele RE,
Franco OE, Wilson L, Singh P, Buskin A, Crawford SE, Gaughan L, et
al: Propagation of human prostate tissue from induced pluripotent
stem cells. Stem Cells Transl Med. 9:734–745. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Fitzgerald KA, Guo J, Tierney EG, Curtin
CM, Malhotra M, Darcy R, O'Brien FJ and O'Driscoll CM: The use of
collagen-based scaffolds to simulate prostate cancer bone
metastases with potential for evaluating delivery of
nanoparticulate gene therapeutics. Biomaterials. 66:53–66. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Katti KS, Jasuja H, Kar S and Katti DR:
Nanostructured biomaterials for in vitro models of bone metastasis
cancer. Curr Opin Biomed Eng. 17:1002542021. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Cruz-Neves S, Ribeiro N, Graça I, Jerónimo
C, Sousa SR and Monteiro FJ: Behavior of prostate cancer cells in a
nanohydroxyapatite/collagen bone scaffold. J Biomed Mater Res A.
105:2035–2046. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Parker C, Castro E, Fizazi K, Heidenreich
A, Ost P, Procopio G, Tombal B and Gillessen S; ESMO Guidelines
Committee. Electronic address, : simpleclinicalguidelines@esmo.org:
Prostate cancer: ESMO clinical practice guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 31:1119–1134. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Kuppen MCP, Westgeest HM, van den Eertwegh
AJM, van Moorselaar RJA, van Oort IM, Tascilar M, Mehra N, Lavalaye
J, Somford DM, Aben KKH, et al: Symptomatic skeletal events and the
use of bone health agents in a real-world treated metastatic
castration resistant prostate cancer population: Results from the
CAPRI-study in the netherlands. Clin Genitourin Cancer. 20:43–52.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Benford HL, McGowan NW, Helfrich MH,
Nuttall ME and Rogers MJ: Visualization of bisphosphonate-induced
caspase-3 activity in apoptotic osteoclasts in vitro. Bone.
28:465–473. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Gralow J and Tripathy D: Managing
metastatic bone pain: The role of bisphosphonates. J Pain Symptom
Manage. 33:462–472. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Percival RC, Urwin GH, Harris S, Yates AJ,
Williams JL, Beneton M and Kanis JA: Biochemical and histological
evidence that carcinoma of the prostate is associated with
increased bone resorption. Eur J Surg Oncol. 13:41–49.
1987.PubMed/NCBI
|
|
109
|
Clarke NW, McClure J and George NJ:
Morphometric evidence for bone resorption and replacement in
prostate cancer. Br J Urol. 68:74–80. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Berruti A, Dogliotti L, Tucci M, Tarabuzzi
R, Fontana D and Angeli A: Metabolic bone disease induced by
prostate cancer: Rationale for the use of bisphosphonates. J Urol.
166:2023–2031. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Small EJ, Smith MR, Seaman JJ, Petrone S
and Kowalski MO: Combined analysis of two multicenter, randomized,
placebo-controlled studies of pamidronate disodium for the
palliation of bone pain in men with metastatic prostate cancer. J
Clin Oncol. 21:4277–4284. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Liu J, Zhao C, Liu B, Liu H and Wang L:
Analgesia and curative effect of pamidronate disodium combined with
chemotherapy on elderly patients with advanced metastatic bone
cancer. Oncol Lett. 18:771–775. 2019.PubMed/NCBI
|
|
113
|
Widler L, Jaeggi KA, Glatt M, Müller K,
Bachmann R, Bisping M, Born AR, Cortesi R, Guiglia G, Jeker H, et
al: Highly potent geminal bisphosphonates. From pamidronate
disodium (Aredia) to zoledronic acid (Zometa). J Med Chem.
45:3721–3738. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Finianos A and Aragon-Ching JB: Zoledronic
acid for the treatment of prostate cancer. Expert Opin
Pharmacother. 20:657–666. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Kamba T, Kamoto T, Maruo S, Kikuchi T,
Shimizu Y, Namiki S, Fujimoto K, Kawanishi H, Sato F, Narita S, et
al: A phase III multicenter, randomized, controlled study of
combined androgen blockade with versus without zoledronic acid in
prostate cancer patients with metastatic bone disease: Results of
the ZAPCA trial. Int J Clin Oncol. 22:166–173. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Weinfurt KP, Anstrom KJ, Castel LD,
Schulman KA and Saad F: Effect of zoledronic acid on pain
associated with bone metastasis in patients with prostate cancer.
Ann Oncol. 17:986–989. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
NICE. Prostate cancer, . Diagnosis and
management. 2019.15/12/2021 [cited 2022 21/11/2022]; Available
from:. https://www.nice.org.uk/guidance/ng131/chapter/Recommendations
|
|
118
|
Fizazi K, Carducci M, Smith M, Damião R,
Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, et al:
Denosumab versus zoledronic acid for treatment of bone metastases
in men with castration-resistant prostate cancer: A randomised,
double-blind study. Lancet. 377:813–822. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Xie J, Namjoshi M, Wu EQ, Parikh K, Diener
M, Yu AP, Guo A and Culver KW: Economic evaluation of denosumab
compared with zoledronic acid in hormone-refractory prostate cancer
patients with bone metastases. J Manag Care Pharm. 17:621–643.
2011.PubMed/NCBI
|
|
120
|
NICE, . Denosumab is not recommended for
preventing skeletal-related events in adults with bone metastases
from prostate cancer. 2012.Available from. https://www.nice.org.uk/donotdo/denosumab-is-not-recommended-for-preventing-skeletalrelated-events-inadults-with-bone-metastases-from-prostate-cancer
|
|
121
|
Smart JG: The use of P32 in the treatment
of severe pain from bone metastases of carcinoma of the prostate1.
Br J Urol. 37:139–147. 1965. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Porter AT, McEwan AJ, Powe JE, Reid R,
McGowan DG, Lukka H, Sathyanarayana JR, Yakemchuk VN, Thomas GM,
Erlich LE, et al: Results of a randomized phase-III trial to
evaluate the efficacy of strontium-89 adjuvant to local field
external beam irradiation in the management of endocrine resistant
metastatic prostate cancer. Int J Radiat Oncol Biol Phys.
25:805–813. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Serafini AN, Houston SJ, Resche I, Quick
DP, Grund FM, Ell PJ, Bertrand A, Ahmann FR, Orihuela E, Reid RH,
et al: Palliation of pain associated with metastatic bone cancer
using samarium-153 lexidronam: A double-blind placebo-controlled
clinical trial. J Clin Oncol. 16:1574–1581. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Sartor O, Reid RH, Hoskin PJ, Quick DP,
Ell PJ, Coleman RE, Kotler JA, Freeman LM and Olivier P; Quadramet
424Sm10/11 Study Group, : Samarium-153-lexidronam complex for
treatment of painful bone metastases in hormone-refractory prostate
cancer. Urology. 63:940–945. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Powers E, Karachaliou GS, Kao C, Harrison
MR, Hoimes CJ, George DJ, Armstrong AJ and Zhang T: Novel therapies
are changing treatment paradigms in metastatic prostate cancer. J
Hematol Oncol. 13:1442020. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Terrisse S, Karamouza E, Parker CC, Sartor
AO, James ND, Pirrie S, Collette L, Tombal BF, Chahoud J, Smeland
S, et al: Overall survival in men with bone metastases from
castration-resistant prostate cancer treated with bone-targeting
radioisotopes: A meta-analysis of individual patient data from
randomized clinical trials. JAMA Oncol. 6:206–216. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Den RB, George D, Pieczonka C and McNamara
M: Ra-223 treatment for bone metastases in castrate-resistant
prostate cancer: Practical management issues for patient selection.
Am J Clin Oncol. 42:399–406. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Parker C, Nilsson S, Heinrich D, Helle SI,
O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, et
al: Alpha emitter radium-223 and survival in metastatic prostate
cancer. N Engl J Med. 369:213–223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Nilsson S, Cislo P, Sartor O, Vogelzang
NJ, Coleman RE, O'Sullivan JM, Reuning-Scherer J, Shan M, Zhan L
and Parker C: Patient-reported quality-of-life analysis of
radium-223 dichloride from the phase III ALSYMPCA study. Ann Oncol.
27:868–874. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Gutman EB, Sproul EE and Gutman AB:
Significance of increased phosphatase activity of bone at the site
of osteoplastic metastases secondary to carcinoma of the prostate
gland. Am J Cancer. 28:485–495. 1936. View Article : Google Scholar
|
|
131
|
Ozu C, Nakashima J, Horiguchi Y, Oya M,
Ohigashi T and Murai M: Prediction of bone metastases by
combination of tartrate-resistant acid phosphatase, alkaline
phosphatase and prostate specific antigen in patients with prostate
cancer. Int J Urol. 15:419–422. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Larson SR, Chin J, Zhang X, Brown LG,
Coleman IM, Lakely B, Tenniswood M, Corey E, Nelson PS, Vessella RL
and Morrissey C: Prostate cancer derived prostatic acid phosphatase
promotes an osteoblastic response in the bone microenvironment.
Clin Exp Metastasis. 31:247–256. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Cheever MA and Higano CS: PROVENGE
(Sipuleucel-T) in prostate cancer: The first FDA-approved
therapeutic cancer vaccine. Clin Cancer Res. 17:3520–3526. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Wargowski E, Johnson LE, Eickhoff JC,
Delmastro L, Staab MJ, Liu G and McNeel DG: Prime-boost vaccination
targeting prostatic acid phosphatase (PAP) in patients with
metastatic castration-resistant prostate cancer (mCRPC) using
sipuleucel-T and a DNA vaccine. J Immunother Cancer. 6:212018.
View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Higano CS, Schellhammer PF, Small EJ,
Burch PA, Nemunaitis J, Yuh L, Provost N and Frohlich MW:
Integrated data from 2 randomized, double-blind,
placebo-controlled, phase 3 trials of active cellular immunotherapy
with sipuleucel-T in advanced prostate cancer. Cancer.
115:3670–3679. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Marshall CH, Fu W, Wang H, Park JC,
DeWeese TL, Tran PT, Song DY, King S, Afful M, Hurrelbrink J, et
al: Randomized phase II trial of sipuleucel-T with or without
radium-223 in men with bone-metastatic castration-resistant
prostate cancer. Clin Cancer Res. 27:1623–1630. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Kasperk CH, Börcsök I, Schairer HU,
Schneider U, Nawroth PP, Niethard FU and Ziegler R: Endothelin-1 is
a potent regulator of human bone cell metabolism in vitro. Calcif
Tissue Int. 60:368–374. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Montironi R, Mazzucchelli R, Barbisan F,
Stramazzotti D, Santinelli A, Lòpez Beltran A, Cheng L, Montorsi F
and Scarpelli M: Immunohistochemical expression of endothelin-1 and
endothelin-A and endothelin-B receptors in high-grade prostatic
intraepithelial neoplasia and prostate cancer. Eur Urol.
52:1682–1690. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Vogelzang NJ, Nelson JB, Schulman CC,
Dearnaley DP, Saad F, Sleep DJ, Isaacson D and Carducci MA:
Meta-analysis of clinical trials of atrasentan 10 mg in metastatic
hormone-refractory prostate cancer. J Clin Oncol. 23 (Suppl
16):S45632005. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Carducci MA, Saad F, Abrahamsson PA,
Dearnaley DP, Schulman CC, North SA, Sleep DJ, Isaacson JD and
Nelson JB; Atrasentan Phase III Study Group Institutions, : A phase
3 randomized controlled trial of the efficacy and safety of
atrasentan in men with metastatic hormone-refractory prostate
cancer. Cancer. 110:1959–1966. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Drake JM, Danke JR and Henry MD:
Bone-specific growth inhibition of prostate cancer metastasis by
atrasentan. Cancer Biol Ther. 9:607–614. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Quinn DI, Tangen CM, Hussain M, Lara PN
Jr, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA,
Monk JP, et al: Docetaxel and atrasentan versus docetaxel and
placebo for men with advanced castration-resistant prostate cancer
(SWOG S0421): A randomised phase 3 trial. Lancet Oncol. 14:893–900.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Teo MY, Rathkopf DE and Kantoff P:
Treatment of advanced prostate cancer. Annu Rev Med. 70:479–499.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Selvaggi G and Scagliotti GV: Management
of bone metastases in cancer: A review. Crit Rev Oncol Hematol.
56:365–378. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Keller ET and Brown J: Prostate cancer
bone metastases promote both osteolytic and osteoblastic activity.
J Cell Biochem. 91:718–729. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Li D, Lv H, Hao X, Hu B and Song Y:
Prognostic value of serum alkaline phosphatase in the survival of
prostate cancer: Evidence from a meta-analysis. Cancer Manag Res.
10:3125–3139. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Karhade AV, Thio QCBS, Kuverji M, Ogink
PT, Ferrone ML and Schwab JH: Prognostic value of serum alkaline
phosphatase in spinal metastatic disease. Br J Cancer. 120:640–646.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Tucci M, Mosca A, Lamanna G, Porpiglia F,
Terzolo M, Vana F, Cracco C, Russo L, Gorzegno G, Tampellini M, et
al: Prognostic significance of disordered calcium metabolism in
hormone-refractory prostate cancer patients with metastatic bone
disease. Prostate Cancer Prostatic Dis. 12:94–99. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Skinner HG and Schwartz GG: Serum calcium
and incident and fatal prostate cancer in the national health and
nutrition examination survey. Cancer Epidemiol Biomarkers Prev.
17:2302–3205. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Francini G, Petrioli R, Gonnelli S,
Correale P, Pozzessere D, Marsili S, Montagnani A, Lucani B, Rossi
S, Monaco R, et al: Urinary calcium excretion in the monitoring of
bone metastases from prostatic carcinoma. Cancer. 92:1468–1474.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Jung K, Lein M, Stephan C, Von Hösslin K,
Semjonow A, Sinha P, Loening SA and Schnorr D: Comparison of 10
serum bone turnover markers in prostate carcinoma patients with
bone metastatic spread: Diagnostic and prognostic implications. Int
J Cancer. 111:783–791. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Cooper EH, Whelan P and Purves D: Bone
alkaline phosphatase and prostate-specific antigen in the
monitoring of prostate cancer. Prostate. 25:236–242. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Kylmälä T, Tammela TL, Risteli L, Risteli
J, Kontturi M and Elomaa I: Type I collagen degradation product
(ICTP) gives information about the nature of bone metastases and
has prognostic value in prostate cancer. Br J Cancer. 71:1061–1064.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Maeda H, Koizumi M, Yoshimura K, Yamauchi
T, Kawai T and Ogata E: Correlation between bone metabolic markers
and bone scan in prostatic cancer. J Urol. 157:539–543. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Klepzig M, Jonas D and Oremek GM:
Procollagen type 1 amino-terminal propeptide: A marker for bone
metastases in prostate carcinoma. Anticancer Res. 29:671–673.
2009.PubMed/NCBI
|
|
156
|
Sundling KE and Lowe AC: Circulating tumor
cells: Overview and opportunities in cytology. Adv Anat Pathol.
26:56–63. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Helo P, Cronin AM, Danila DC, Wenske S,
Gonzalez-Espinoza R, Anand A, Koscuiszka M, Väänänen RM, Pettersson
K, Chun FK, et al: Circulating prostate tumor cells detected by
reverse transcription-PCR in men with localized or
castration-refractory prostate cancer: Concordance with CellSearch
assay and association with bone metastases and with survival. Clin
Chem. 55:765–773. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Josefsson A, Larsson K, Månsson M,
Björkman J, Rohlova E, Åhs D, Brisby H, Damber JE and Welén K:
Circulating tumor cells mirror bone metastatic phenotype in
prostate cancer. Oncotarget. 9:29403–29413. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Saxby H, Mikropoulos C and Boussios S: An
update on the prognostic and predictive serum biomarkers in
metastatic prostate cancer. Diagnostics (Basel). 10:5492020.
View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Zhang HL, Yang LF, Zhu Y, Yao XD, Zhang
SL, Dai B, Zhu YP, Shen YJ, Shi GH and Ye DW: Serum miRNA-21:
Elevated levels in patients with metastatic hormone-refractory
prostate cancer and potential predictive factor for the efficacy of
docetaxel-based chemotherapy. Prostate. 71:326–331. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Bhagirath D, Yang TL, Bucay N, Sekhon K,
Majid S, Shahryari V, Dahiya R, Tanaka Y and Saini S: microRNA-1246
is an exosomal biomarker for aggressive prostate cancer. Cancer
Res. 78:1833–1844. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Tinay I, Tan M, Gui B, Werner L, Kibel AS
and Jia L: Functional roles and potential clinical application of
miRNA-345-5p in prostate cancer. Prostate. 78:927–937. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Roest HP, IJzermans JNM and van der Laan
LJW: Evaluation of RNA isolation methods for microRNA
quantification in a range of clinical biofluids. BMC Biotechnol.
21:482021. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Guo X, Han T, Hu P, Guo X, Zhu C, Wang Y
and Chang S: Five microRNAs in serum as potential biomarkers for
prostate cancer risk assessment and therapeutic intervention. Int
Urol Nephrol. 50:2193–2200. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Yamada Y, Nishikawa R, Kato M, Okato A,
Arai T, Kojima S, Yamazaki K, Naya Y, Ichikawa T and Seki N:
Regulation of HMGB3 by antitumor miR-205-5p inhibits cancer cell
aggressiveness and is involved in prostate cancer pathogenesis. J
Hum Genet. 63:195–205. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Casanova-Salas I, Rubio-Briones J,
Fernández-Serra A and López-Guerrero JA: miRNAs as biomarkers in
prostate cancer. Clin Transl Oncol. 14:803–811. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Zhang HL, Qin XJ, Cao DL, Zhu Y, Yao XD,
Zhang SL, Dai B and Ye DW: An elevated serum miR-141 level in
patients with bone-metastatic prostate cancer is correlated with
more bone lesions. Asian J Androl. 15:231–235. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Nordby Y, Richardsen E, Ness N, Donnem T,
Patel HRH, Busund LT, Bremnes RM and Andersen S: High miR-205
expression in normal epithelium is associated with biochemical
failure-an argument for epithelial crosstalk in prostate cancer?
Sci Rep. 7:163082017. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Haflidadóttir BS, Larne O, Martin M,
Persson M, Edsjö A, Bjartell A and Ceder Y: Upregulation of miR-96
enhances cellular proliferation of prostate cancer cells through
FOXO1. PLoS One. 8:e724002013. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Ma Y, Yang HZ, Dong BJ, Zou HB, Zhou Y,
Kong XM and Huang YR: Biphasic regulation of autophagy by miR-96 in
prostate cancer cells under hypoxia. Oncotarget. 5:9169–9182. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Bonci D, Coppola V, Patrizii M, Addario A,
Cannistraci A, Francescangeli F, Pecci R, Muto G, Collura D, Bedini
R, et al: A microRNA code for prostate cancer metastasis. Oncogene.
35:1180–1192. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Tang Y, Wu B, Huang S, Peng X, Li X, Huang
X, Zhou W, Xie P and He P: Downregulation of miR-505-3p predicts
poor bone metastasis-free survival in prostate cancer. Oncol Rep.
41:57–66. 2019.PubMed/NCBI
|
|
173
|
Olivan M, Garcia M, Suárez L, Guiu M, Gros
L, Méndez O, Rigau M, Reventós J, Segura MF, de Torres I, et al:
Loss of microRNA-135b enhances bone metastasis in prostate cancer
and predicts aggressiveness in human prostate samples. Cancers
(Basel). 13:62022021. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Aigner A and Fischer D:
Nanoparticle-mediated delivery of small RNA molecules in tumor
therapy. Pharmazie. 71:27–34. 2016.PubMed/NCBI
|
|
175
|
Oh-Hohenhorst SJ and Lange T: Role of
metastasis-related microRNAs in prostate cancer progression and
treatment. Cancers (Basel). 13:44922021. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Abramovic I, Ulamec M, Katusic Bojanac A,
Bulic-Jakus F, Jezek D and Sincic N: miRNA in prostate cancer:
Challenges toward translation. Epigenomics. 12:543–558. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Locati MD, Terpstra I, de Leeuw WC, Kuzak
M, Rauwerda H, Ensink WA, van Leeuwen S, Nehrdich U, Spaink HP,
Jonker MJ, et al: Improving small RNA-seq by using a synthetic
spike-in set for size-range quality control together with a set for
data normalization. Nucleic Acids Res. 43:e892015. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Zhang W, Zang J, Jing X, Sun Z, Yan W,
Yang D, Shen B and Guo F: Identification of candidate miRNA
biomarkers from miRNA regulatory network with application to
prostate cancer. J Transl Med. 12:662014. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Pashaei E, Pashaei E, Ahmady M, Ozen M and
Aydin N: Meta-analysis of miRNA expression profiles for prostate
cancer recurrence following radical prostatectomy. PLoS One.
12:e01795432017. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Sottnik JL and Keller ET: Understanding
and targeting osteoclastic activity in prostate cancer bone
metastases. Curr Mol Med. 13:626–639. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Macherey S, Monsef I, Jahn F, Jordan K,
Yuen KK, Heidenreich A and Skoetz N: Bisphosphonates for advanced
prostate cancer. Cochrane Database Syst Rev.
12:Cd0062502017.PubMed/NCBI
|
|
182
|
Elomaa I, Kylmälä T, Tammela T, Viitanen
J, Ottelin J, Ruutu M, Jauhiainen K, Ala-Opas M, Roos L, Seppänen
J, et al: Effect of oral clodronate on bone pain. A controlled
study in patients with metastic prostatic cancer. Int Urol Nephrol.
24:159–166. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Vorreuther R, Klotz T and Engelking R:
Clodronate in the palliative therapy of bone-metastasized prostatic
carcinoma. Urologe A. 31:63–66. 1992.(In German). PubMed/NCBI
|
|
184
|
Adami S and Mian M: Clodronate therapy of
metastatic bone disease in patients with prostatic carcinoma.
Recent Results Cancer Res. 116:67–72. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Strang P, Nilsson S, Brändstedt S, Sehlin
J, Borghede G, Varenhorst E, Bandman U, Borck L, Englund G and
Selin L: The analgesic efficacy of clodronate compared with placebo
in patients with painful bone metastases from prostatic cancer.
Anticancer Res. 17:4717–4721. 1997.PubMed/NCBI
|
|
186
|
Kylmälä T, Taube T, Tammela TL, Risteli L,
Risteli J and Elomaa I: Concomitant i.v. and oral clodronate in the
relief of bone pain-a double-blind placebo-controlled study in
patients with prostate cancer. Br J Cancer. 76:939–942. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Ernst DS, Tannock IF, Winquist EW, Venner
PM, Reyno L, Moore MJ, Chi K, Ding K, Elliott C and Parulekar W:
Randomized, double-blind, controlled trial of
mitoxantrone/prednisone and clodronate versus
mitoxantrone/prednisone and placebo in patients with
hormone-refractory prostate cancer and pain. J Clin Oncol.
21:3335–3342. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Mason MD, Sydes MR, Glaholm J, Langley RE,
Huddart RA, Sokal M, Stott M, Robinson AC, James ND, Parmar MK, et
al: Oral sodium clodronate for nonmetastatic prostate
cancer-results of a randomized double-blind placebo-controlled
trial: Medical research council PR04 (ISRCTN61384873). J Natl
Cancer Inst. 99:765–776. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Dearnaley DP, Sydes MR, Mason MD, Stott M,
Powell CS, Robinson AC, Thompson PM, Moffat LE, Naylor SL and
Parmar MK; Mrc Pr05 Collaborators, : A double-blind,
placebo-controlled, randomized trial of oral sodium clodronate for
metastatic prostate cancer (MRC PR05 trial). J Natl Cancer Inst.
95:1300–1311. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Dearnaley DP, Mason MD, Parmar MK, Sanders
K and Sydes MR: Adjuvant therapy with oral sodium clodronate in
locally advanced and metastatic prostate cancer: Long-term overall
survival results from the MRC PR04 and PR05 randomised controlled
trials. Lancet Oncol. 10:872–876. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Lipton A, Glover D, Harvey H, Grabelsky S,
Zelenakas K, Macerata R and Seaman J: Pamidronate in the treatment
of bone metastases: Results of 2 dose-ranging trials in patients
with breast or prostate cancer. Ann Oncol. 5 (Suppl 7):S31–S35.
1994.PubMed/NCBI
|
|
192
|
Figg WD, Liu Y, Arlen P, Gulley J,
Steinberg SM, Liewehr DJ, Cox MC, Zhai S, Cremers S, Parr A, et al:
A randomized, phase II trial of ketoconazole plus alendronate
versus ketoconazole alone in patients with androgen independent
prostate cancer and bone metastases. J Urol. 173:790–796. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Sweeney C, Dugan WM II, Dreicer R, Chu F,
Parks G, Baker K, Reed D, Jansz K, Zadra J and Yiannoutsos CT: A
randomized placebo-controlled trial of daily high-dose oral
risedronate in men with metastatic prostate cancer commencing
androgen deprivation therapy (ADT). J Clin Oncol. 28 (15
Suppl):e150002010. View Article : Google Scholar
|
|
194
|
Meulenbeld HJ, van Werkhoven ED, Coenen
JL, Creemers GJ, Loosveld OJ, de Jong PC, Ten Tije AJ, Fosså SD,
Polee M, Gerritsen W, et al: Randomised phase II/III study of
docetaxel with or without risedronate in patients with metastatic
castration resistant prostate cancer (CRPC), the Netherlands
prostate study (NePro). Eur J Cancer. 48:2993–3000. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Hahn NM, Yiannoutsos CT, Kirkpatrick K,
Sharma J and Sweeney CJ: Failure to suppress markers of bone
turnover on first-line hormone therapy for metastatic prostate
cancer is associated with shorter time to skeletal-related event.
Clin Genitourin Cancer. 12:33–40.e4. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Hoskin P, Sundar S, Reczko K, Forsyth S,
Mithal N, Sizer B, Bloomfield D, Upadhyay S, Wilson P, Kirkwood A,
et al: A multicenter randomized trial of ibandronate compared with
single-dose radiotherapy for localized metastatic bone pain in
prostate cancer. J Natl Cancer Inst. 107:djv1972015. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Saad F, Gleason DM, Murray R, Tchekmedyian
S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA and Chen B;
Zoledronic Acid Prostate Cancer Study Group, : A randomized,
placebo-controlled trial of zoledronic acid in patients with
hormone-refractory metastatic prostate carcinoma. J Natl Cancer
Inst. 94:1458–1468. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Abetz L, Barghout V, Arbuckle R, Bosch V,
Shirina N and Saad F: Impact of zoledronic acid (Z) on pain in
prostate cancer patients with bone metastases in a randomised
placebo-control trial. J Clin Oncol. 24 (Suppl 18):S46382006.
View Article : Google Scholar
|
|
199
|
Leto G, Badalamenti G, Arcara C,
Crescimanno M, Flandina C, Tumminello FM, Incorvaia L, Gebbia N and
Fulfaro F: Effects of zoledronic acid on proteinase plasma levels
in patients with bone metastases. Anticancer Res. 26:23–26.
2006.PubMed/NCBI
|
|
200
|
Cózar Olmo JM, Carballido Rodriguez J,
Luque Galvez P, Tabernero Gómez AG, Barreiro Mouro A, Sánchez
Sánchez E, González Enguita C, Alcover García J, Garcia-Galisteo E,
Abascal García JM, et al: Effectiveness and tolerability of
zoledronic acid in the treatment of metastatic prostate cancer.
Actas Urol Esp. 32:492–501. 2008.(In Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Saad F, Gleason DM, Murray R, Tchekmedyian
S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA and Zheng M;
Zoledronic Acid Prostate Cancer Study Group, : Long-term efficacy
of zoledronic acid for the prevention of skeletal complications in
patients with metastatic hormone-refractory prostate cancer. J Natl
Cancer Inst. 96:879–882. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Fulfaro F, Leto G, Badalamenti G, Arcara
C, Cicero G, Valerio MR, Di Fede G, Russo A, Vitale A, Rini GB, et
al: The use of zoledronic acid in patients with bone metastases
from prostate carcinoma: Effect on analgesic response and bone
metabolism biomarkers. J Chemother. 17:555–559. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Saad F: Clinical benefit of zoledronic
acid for the prevention of skeletal complications in advanced
prostate cancer. Clin Prostate Cancer. 4:31–37. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Saad F, Chen YM, Gleason DM and Chin J:
Continuing benefit of zoledronic acid in preventing skeletal
complications in patients with bone metastases. Clin Genitourin
Cancer. 5:390–396. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Saad F and Eastham J: Zoledronic acid
improves clinical outcomes when administered before onset of bone
pain in patients with prostate cancer. Urology. 76:1175–1181. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Paparella S, Finkelberg E, Varisco D,
Tondelli E and Rocco F: Use of zoledronic acid in patients with
prostate cancer bone metastases: Control of pain and
musculoskeletal complications. Urologia. 78:300–304. 2011.(In
Italian). View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Uemura H, Yanagisawa M, Ikeda I, Fujinami
K, Iwasaki A, Noguchi S, Noguchi K and Kubota Y; Yokohama Bone
Metastasis Study Group, : Possible anti-tumor activity of initial
treatment with zoledronic acid with hormonal therapy for
bone-metastatic prostate cancer in multicenter clinical trial. Int
J Clin Oncol. 18:472–477. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Wang F, Chen W, Chen H, Mo L, Jin H, Yu Z,
Li C, Liu Q, Duan F and Weng Z: Comparison between zoledronic acid
and clodronate in the treatment of prostate cancer patients with
bone metastases. Med Oncol. 30:6572013. View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Ueno S, Mizokami A, Fukagai T, Fujimoto N,
Oh-Oka H, Kondo Y, Arai G, Ide H, Horie S, Ueki O, et al: Efficacy
of combined androgen blockade with zoledronic acid treatment in
prostate cancer with bone metastasis: The ZABTON-PC (zoledronic
acid/androgen blockade trial on prostate cancer) study. Anticancer
Res. 33:3837–3844. 2013.PubMed/NCBI
|
|
210
|
Chiang PH, Wang HC, Lai YL, Chen SC,
Yen-Hwa W, Kok CK, Ou YC, Huang JS, Huang TC and Chao TY:
Zoledronic acid treatment for cancerous bone metastases: A phase IV
study in Taiwan. J Cancer Res Ther. 9:653–659. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
211
|
Pan Y, Jin H, Chen W, Yu Z, Ye T, Zheng Y,
Weng Z and Wang F: Docetaxel with or without zoledronic acid for
castration-resistant prostate cancer. Int Urol Nephrol.
46:2319–2326. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Smith MR, Halabi S, Ryan CJ, Hussain A,
Vogelzang N, Stadler W, Hauke RJ, Monk JP, Saylor P, Bhoopalam N,
et al: Randomized controlled trial of early zoledronic acid in men
with castration-sensitive prostate cancer and bone metastases:
Results of CALGB 90202 (alliance). J Clin Oncol. 32:1143–1150.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Wirth M, Tammela T, Cicalese V, Gomez
Veiga F, Delaere K, Miller K, Tubaro A, Schulze M, Debruyne F,
Huland H, et al: Prevention of bone metastases in patients with
high-risk nonmetastatic prostate cancer treated with zoledronic
acid: Efficacy and safety results of the Zometa European Study
(ZEUS). Eur Urol. 67:482–491. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
214
|
James ND, Pirrie SJ, Pope AM, Barton D,
Andronis L, Goranitis I, Collins S, Daunton A, McLaren D,
O'Sullivan J, et al: Clinical outcomes and survival following
treatment of metastatic castrate-refractory prostate cancer with
docetaxel alone or with strontium-89, zoledronic acid, or both: The
TRAPEZE randomized clinical trial. JAMA Oncol. 2:493–499. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
215
|
Denham JW, Wilcox C, Joseph D, Spry NA,
Lamb DS, Tai KH, Matthews J, Atkinson C, Turner S, Christie D, et
al: Quality of life in men with locally advanced prostate cancer
treated with leuprorelin and radiotherapy with or without
zoledronic acid (TROG 03.04 RADAR): Secondary endpoints from a
randomised phase 3 factorial trial. Lancet Oncol. 13:1260–1270.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
216
|
Denham JW, Joseph D, Lamb DS, Spry NA,
Duchesne G, Matthews J, Atkinson C, Tai KH, Christie D, Kenny L, et
al: Short-term androgen suppression and radiotherapy versus
intermediate-term androgen suppression and radiotherapy, with or
without zoledronic acid, in men with locally advanced prostate
cancer (TROG 03.04 RADAR): An open-label, randomised, phase 3
factorial trial. Lancet Oncol. 15:1076–1089. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
217
|
Denham JW, Joseph D, Lamb DS, Spry NA,
Duchesne G, Matthews J, Atkinson C, Tai KH, Christie D, Kenny L, et
al: Short-term androgen suppression and radiotherapy versus
intermediate-term androgen suppression and radiotherapy, with or
without zoledronic acid, in men with locally advanced prostate
cancer (TROG 03.04 RADAR): 10-Year results from a randomised, phase
3, factorial trial. Lancet Oncol. 20:267–281. 2019. View Article : Google Scholar : PubMed/NCBI
|
